EndoRobotics Co., Ltd.
PrivateLast Round
Series C
Dec 2, 2025
Est. Valuation
$114.9M
Total Funding Raised
$64.4M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
EndoRobotics Co., Ltd. operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series C round in December 2025.
EndoRobotics Co., Ltd. is a medical device company that develops and manufactures endoscopic robotic equipment designed to support non-invasive therapeutic procedures in gastroenterology.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Industrial Robotics
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Hardware + Subscription
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EndoRobotics Co., Ltd. Comparables
Compare EndoRobotics Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Endo Tools Therapeutics | 82% | |
| EndoQuest Robotics | 81% | |
| Lumendi | 78% |
For institutional investors. Book with your work email.
EndoRobotics Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Dec 2, 2025 | ||||
| Series B Extension | May 7, 2024 | ||||
| Series C | Dec 2, 2023 | ||||
| Series B | Aug 1, 2023 | ||||
| Series A | Aug 25, 2021 | ||||
Pre Seed | Jun 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EndoRobotics Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KOTEC | Series C |
| Korea University Holdings | Seed |
| KNET Investment Partners | Series C, Series A |
| K-Ground Ventures | Series C, Series A |
| Premier Partners | Series B, Series C |
| Seoul Business Agency | Series A |
| K-Net Investment Partners | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
Open roles increased to 10, 24% of headcount.
- Sep 25, 2026
Grew 15% QoQ, from 39 to 45 employees.
For institutional investors. Book with your work email.
EndoRobotics Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EndoRobotics Co., Ltd.'s valuation, stock price, and market status.
Is EndoRobotics Co., Ltd. a public or private company?
EndoRobotics Co., Ltd. is a private company.
What is the current stock price of EndoRobotics Co., Ltd.?
EndoRobotics Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks EndoRobotics Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EndoRobotics Co., Ltd. worth (valuation)?
EndoRobotics Co., Ltd.'s valuation is estimated at $114.9M based on funding round data.
Can I buy EndoRobotics Co., Ltd. stock?
EndoRobotics Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EndoRobotics Co., Ltd.'s last funding round?
EndoRobotics Co., Ltd.'s most recent funding round was Series C on December 2, 2025.
Who are the main investors in EndoRobotics Co., Ltd.?
Key investors in EndoRobotics Co., Ltd. include Premier Partners, Magna Investment.
Will EndoRobotics Co., Ltd. IPO soon?
No public IPO plans have been announced for EndoRobotics Co., Ltd..
How can I track EndoRobotics Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in EndoRobotics Co., Ltd.'s shares on secondary markets.